Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2mut breast tumors

Key Points

• The aim is to assess the effectiveness of combined PARP and AKT inhibitors in preventing tumor development in BRCA1/2 mutant breast cancers.
• Used K14-Cre Brca1 f/f Tp53 f/f mouse model.
• Administered PARP inhibitor alone and in combination with AKT inhibitor.
• Monitored tumor development and growth in treated mice.
• PARP inhibitor alone did not prevent tumor development.
• Combination of PARP and AKT inhibitors intercepted existing tumors but did not stop new tumors.
• Findings support the efficacy of targeting PI3K signaling in BRCA1/2-related tumor strategies.